BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 12:19:00 PM | Browse: 781 | Download: 526
Publication Name World Journal of Hepatology
Manuscript ID 11371
Country/Territory Greece
2014-05-18 16:10
Peer-Review Started
2014-05-18 22:44
To Make the First Decision
2014-06-06 11:02
Return for Revision
2014-06-16 11:10
2014-06-22 22:48
Second Decision
2014-09-10 13:39
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-09-10 14:01
Articles in Press
2014-09-10 14:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-10-27 15:03
Publish the Manuscript Online
2014-11-05 09:07
ISSN 1948-5182 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Minireviews
Article Title Lipid-lowering agents in the management of nonalcoholic fatty liver disease
Manuscript Source Invited Manuscript
All Author List Konstantinos Tziomalos
Funding Agency and Grant Number
Corresponding author Konstantinos Tziomalos, MD, PhD, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Kiriakidi 1, 54636 Thessaloniki, Greece. ktziomalos@yahoo.com
Keywords Nonalcoholic fatty liver disease; Statins; Fibrates; Ezetimibe; Colesevelam; Omega-3 fatty acids; Nicotinic acid; Cardiovascular disease; Transaminases; Nonalcoholic steatohepatitis
Core Tip Accumulating data suggest that statins are safe in patients with nonalcoholic fatty liver disease (NAFLD) and that they reduce the increased cardiovascular morbidity of this population. However, it is still unclear whether statins are also useful as a treatment for NAFLD per se, since there are very limited and conflicting data on their effects on liver histology. There is also very scarce evidence regarding the safety and efficacy of other lipid-lowering agents in patients with NAFLD.
Publish Date 2014-11-05 09:07
Citation Tziomalos K. Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World J Hepatol 2014; 6(10): 738-744
Url http://www.wjgnet.com/1948-5182/full/v6/i10/738.htm
DOI http://dx.doi.org/10.4254/wjh.v6.i10.738
Full Article (PDF) WJH-6-738.pdf
Full Article (Word) WJH-6-738.doc
Manuscript File 11371-Review.docx
Answering Reviewers 11371-Answering reviewers.pdf
Copyright License Agreement 11371-Copyright assignment.pdf
Peer-review Report 11371-Peer review(s).pdf
Scientific Misconduct Check 11371-CrossCheck.jpg
Scientific Editor Work List 11371-Scientific editor work list.pdf